Current status of GP IIb/IIIa inhibitors

Tim Lockie and Simon Redwood

in Oxford Textbook of Interventional Cardiology

Published on behalf of Oxford University Press

ISBN: 9780199569083
Published online July 2011 | e-ISBN: 9780199697816 | DOI:

Series: Oxford Textbooks

Current status of GP IIb/IIIa inhibitors

Show Summary Details


The process of atheromatous plaque rupture is thought to underlie most acute coronary syndromes (ACS) and thus is a major cause of overall morbidity and mortality. As a result, the costs in terms of healthcare expenditure of the consequences of acute plaque rupture are considerable. The immediate and often catastrophic result of plaque rupture is intracoronary thrombosis resulting in vessel occlusion and myocardial infarction (MI). Over the last 20 years there has been a steady decline in the mortality rates from ACS that has resulted from the successful implementation of therapies to attenuate the effects of plaque rupture that include fibrinolysis, percutaneous revascularization, antithrombotic therapy, and plaque stabilization. Glycoprotein (GP) IIb/IIIa receptor inhibitors are agents that have been developed to block the final common pathway that results in platelet aggregation, and following plaque rupture is a key process in coronary thrombosis. Despite the improvement in outcomes from ACS, however, the mortality rate still remains high and there is a need for critical appraisal of the use of currently available agents as well as the need for ongoing research and development of new agents and clinical techniques to improve outcomes further.

Chapter.  14327 words.  Illustrated.

Subjects: Radiology ; Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.